Core Viewpoint - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. has approved the use of idle raised funds and self-owned funds for cash management, with a total limit of up to RMB 1.3 billion, which includes RMB 950 million from raised funds and RMB 350 million from self-owned funds [2][4]. Group 1: Cash Management Approval - The company held meetings on November 29, 2024, and December 18, 2024, to approve the cash management proposal [2]. - The cash management period is set for 12 months from the date of shareholder approval [2]. Group 2: Redemption of Cash Management Products - The company has redeemed cash management products using idle raised funds, with specific details on the amounts and types of products involved [2][3]. - The redemption includes various structured deposit products from banks such as China Everbright Bank and Ningbo Bank [3][6]. Group 3: Cash Management Situation - The company has utilized idle raised funds and self-owned funds for cash management, with a total of RMB 1.013 billion remaining in cash management products, including RMB 818 million from raised funds and RMB 195 million from self-owned funds [8]. - The cash management activities are conducted without affecting the company's daily operations and the normal progress of investment projects [5][6]. Group 4: Related Party Relationships - There are no related party relationships between the company and the banks involved in the cash management products [3].